In the article titled "Determination of Serum Lost Goodwill Target Proteome in Patients with Severe Traumatic Brain Injury" , there was an incomplete description of how the results related to our earlier publications. The predictive value of LGT in TBI was also overestimated. We apologise for this and explain below the relationship between our articles, why we classified the patients as we did, and the use of the grants for this research.
1. Previous Articles
Our earlier work was discussed as follows, which was not sufficient: "Ren et al.  reported that the LGT proteome was produced under the pathologic condition of TBI patients, and the abundance of LGT proteome is closely associated with pathogenetic condition and prognosis of TBI patients; the LGT proteome may play an important role in predicting pathogenetic condition and prognosis of TBI patients."
Our three earlier articles also studied serum LGT expression as a potential biomarker in traumatic brain injury. A summary of our four articles is listed in Table 1.
Comparing all types of patients, we believed that the LGT proteome is more important in severe traumatic brain injury (TBI). Thus, in later studies and case collection we focused on severe TBI. Some patients/data were shared between the articles, though there was a different emphasis for each study. The present article  contains the final summary of severe TBI.
In the section "The Innovation", we stated "Serum LGT proteome was detected by surface enhanced laser desorption/ionisation time-of-flight mass spectrometer (SELDI-TOF-MS). The LGT proteome presents in the serum of severe TBI patients. The abundance diversity of LGT proteome is intimately associated with pathogenetic condition of TBI patients....